Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Completed · Phase 3

Conditions studied: Choroidal Melanoma

In brief

To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

Key facts

Study ID
NCT00680225
Run by
New England Retina Associates
People needed
10
Starts
2007-09-01
Expected to finish
2012-07-01
Last updated by the study team
2017-04-12

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.